PDS Biotechnology Corporation (PDSB) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
PDS Biotechnology Corporation (PDSB) trades at $0.2089 with AI Score 24/100 (Grade F). PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company specializing in the development of cancer immunotherapies. Market cap: $11.7M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 9, 2026Analyst Coverage for PDSB: PDSB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PDSB against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PDSB: 2/3 scored disciplines lean bearish. Dominant signal: Valuation weak.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
PDS Biotechnology Corporation (PDSB) Healthcare & Pipeline Overview
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm focusing on innovative cancer immunotherapies, notably PDS0101, currently in Phase II trials. The company leverages its proprietary VERSATILE platform to target HPV-associated cancers and is developing additional candidates for prostate, breast, and other cancers, positioning it within the competitive oncology therapeutics landscape.
What Is the Investment Thesis for PDSB?
PDS Biotechnology Corporation presents a notable research candidate due to its innovative VERSATILE platform and promising clinical pipeline. The Phase II trials for PDS0101 targeting HPV-associated cancers represent a near-term value driver. Successful trial outcomes and potential FDA approval could significantly increase the company's market capitalization. The development of additional preclinical candidates targeting various cancers and infectious diseases offers long-term growth potential. However, the company's reliance on clinical trial success and the competitive landscape of the biotechnology industry pose significant risks. As of 2026-05-09, the company has a market cap of $11.7M.
Based on FMP financials and quantitative analysis
PDSB Key Highlights
PDS0101 (HPV16) is in Phase II clinical trials, targeting recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer.
- Developing PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers.
- Developing PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers.
- Developing PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma.
- Collaborations with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH.
Who Are PDSB's Competitors?
PDSB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MRK Merck & Co., Inc. | $152.22 | +12.61% | $376B | 75 |
| BMY Bristol-Myers Squibb Company | $65.47 | -3.17% | $134B | 90 |
| GILD Gilead Sciences, Inc. | $143.44 | -2.82% | $178B | 62 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PDSB's Key Strengths?
Innovative VERSATILE platform for cancer immunotherapy.
- Lead product candidate (PDS0101) in Phase II clinical trials.
- Pipeline of preclinical candidates targeting various cancers and infectious diseases.
- Strategic collaborations with reputable institutions.
What Are PDSB's Weaknesses?
Clinical-stage company with no currently approved products.
- Reliance on clinical trial success and regulatory approvals.
- Limited financial resources compared to larger pharmaceutical companies.
- High risk of failure associated with drug development.
What Could Drive PDSB Stock Higher?
PDSB catalyst: Phase II clinical trial results for PDS0101 in recurrent/metastatic head and neck cancer (expected in late 2026).
- Initiation of Phase I clinical trials for PDS0102 (TARP) in prostate and breast cancers (expected in early 2027).
- Expansion of strategic collaborations with pharmaceutical companies for co-development and commercialization.
- Progress in preclinical development of vaccine candidates for tuberculosis, influenza, and COVID-19.
What Are the Key Risks for PDSB?
Financial-distress signal — its Altman Z-Score of -47.50 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Unfavorable clinical trial results for PDS0101 or other product candidates.
- Regulatory delays or rejection of marketing applications.
- Competition from established pharmaceutical companies and other biotech firms.
- Dependence on securing additional funding to support clinical development and operations.
- Patent challenges and intellectual property disputes.
What Are the Growth Opportunities for PDSB?
- Expansion of PDS0101 into additional HPV-associated cancers: PDS Biotechnology can leverage the ongoing Phase II trials of PDS0101 to expand its application to other HPV-related cancers beyond head and neck and cervical cancers. This includes anal, penile, and vaginal cancers, representing a significant untapped market. Success in these indications could broaden the addressable patient population and increase revenue potential. The timeline for expansion would depend on clinical trial results and regulatory approvals.
- Advancement of preclinical candidates into clinical trials: PDS Biotechnology's pipeline includes several preclinical candidates targeting various cancers, such as PDS0102 (TARP) for prostate and breast cancers and PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers. Progressing these candidates into Phase I clinical trials would be a major growth catalyst, demonstrating the potential of the VERSATILE platform across multiple cancer types. This expansion could attract further investment and partnerships.
- Development of vaccine candidates for infectious diseases: PDS Biotechnology is also developing vaccine candidates for infectious diseases, including tuberculosis (PDS0201), influenza (PDS0202), and COVID-19 (PDS0203). While these programs are in earlier stages of development, successful preclinical and clinical results could open up new revenue streams and diversify the company's portfolio. The market for vaccines remains substantial, driven by ongoing public health needs and emerging infectious disease threats.
- Strategic partnerships and collaborations: PDS Biotechnology can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. Collaborations can provide access to funding, expertise, and distribution networks, enhancing the company's ability to bring its therapies to market. The company already has existing agreements with organizations like Merck and the NIH, which can serve as a foundation for future partnerships.
- Expansion into personalized cancer therapies: The VERSATILE platform could be adapted to develop personalized cancer therapies tailored to individual patients' tumor profiles. This approach involves identifying specific tumor-associated antigens and designing immunotherapies that target those antigens. Personalized cancer therapies represent a growing area of oncology research, offering the potential for more effective and targeted treatments. This could differentiate PDS Biotechnology from competitors focused on more generalized approaches.
What Are PDSB's Competitive Advantages?
- VERSATILE platform technology: The VERSATILE platform is designed to enhance T-cell activation and tumor eradication, potentially offering a more effective approach to cancer immunotherapy.
- Clinical-stage pipeline: The company has a lead product candidate, PDS0101, in Phase II clinical trials, providing a near-term value driver.
- Strategic collaborations: PDS Biotechnology has established collaborations with reputable institutions like the National Institutes of Health and Merck, providing access to expertise and resources.
- Intellectual property: The company owns patents and patent applications covering its VERSATILE platform and product candidates, providing a degree of exclusivity.
What Does PDSB Do?
Founded in 2005 and based in Princeton, New Jersey, PDS Biotechnology Corporation is dedicated to developing multifunctional cancer immunotherapies. The company's core technology is the VERSATILE (Versatile Eliciting Rapid Specific Active T-cells to Immunologically Leverage the Eradication of Tumors) platform, which aims to enhance the body's immune response to fight cancer cells. Their lead product candidate, PDS0101 (HPV16), is in Phase II clinical trials, targeting recurrent/metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. Beyond PDS0101, PDS Biotechnology is developing a pipeline of preclinical product candidates, including PDS0102 (TARP) for prostate and breast cancers, PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers, and PDS0104 (Tyrosinase-related protein 2) for melanoma. The company is also exploring vaccine candidates for infectious diseases, such as PDS0201 for tuberculosis, PDS0202 for influenza, and PDS0203 for COVID-19. PDS Biotechnology has established collaborations and licensing agreements with institutions like the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH to advance its research and development efforts.
What Products and Services Does PDSB Offer?
- Develops cancer immunotherapies using the VERSATILE platform.
- Conducts Phase II clinical trials for PDS0101 (HPV16) targeting HPV-associated cancers.
- Develops preclinical product candidates for prostate, breast, ovarian, colorectal, lung, and melanoma cancers.
- Explores vaccine candidates for tuberculosis, influenza, and COVID-19.
- Establishes collaborations and licensing agreements with research institutions and pharmaceutical companies.
- Focuses on enhancing the body's immune response to fight cancer cells.
How Does PDSB Make Money?
- Develops and patents novel cancer immunotherapies and vaccines.
- Conducts clinical trials to demonstrate the safety and efficacy of its product candidates.
- Seeks regulatory approvals from agencies like the FDA to commercialize its therapies.
- Partners with pharmaceutical companies for manufacturing, distribution, and commercialization.
What Industry Does PDSB Operate In?
PDS Biotechnology operates within the competitive biotechnology industry, focusing on cancer immunotherapies and vaccine development. The market for cancer immunotherapies is experiencing substantial growth, driven by advancements in understanding the immune system's role in fighting cancer. The competitive landscape includes established pharmaceutical companies and smaller biotech firms developing novel therapies. PDS Biotechnology differentiates itself through its VERSATILE platform, which aims to enhance T-cell activation and tumor eradication. Success in this industry hinges on clinical trial outcomes, regulatory approvals, and the ability to secure partnerships and funding.
Who Are PDSB's Key Customers?
- Patients with recurrent/metastatic head and neck cancer.
- Patients with human papillomavirus (HPV)-associated malignancies.
- Patients with cervical cancer.
- Potential future patients with prostate, breast, ovarian, colorectal, lung, and melanoma cancers.
How PDS Biotechnology Corporation Is Valued
PDS Biotechnology Corporation carries a market capitalization of $11.7M, placing it in the micro-cap category. Relative to its peer group, PDSB's quantitative score of 24/100 is below the peer average of 76/100.
Company Profile
PDS Biotechnology Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Princeton, US. The company is led by CEO Frank K. Bedu-Addo. PDSB has traded publicly since 2015.
Key Financial Metrics
A current ratio of 2.26 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -68.8%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
PDS Biotechnology Corporation's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -47.50 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project PDS Biotechnology Corporation revenue of about $11.3M for fiscal 2026, with EPS near $-0.52.
PDSB Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- PDSB's recent insider buying signals strong internal confidence, a classic bullish indicator.
- The buzz around PDSB in social trading communities is overwhelmingly positive, suggesting growing market optimism.
- The company's innovative cancer immunotherapy platform is gaining traction, potentially disrupting the market. Think BioNTech before the COVID vaccine.
- Positive clinical trial updates, even preliminary, are fueling speculation about future revenue streams.
Bear Case
- Despite the hype, PDSB is still pre-revenue, making it a high-risk investment. Remember Theranos' promises?
- The biotech sector is notoriously volatile; a single failed trial could tank the stock.
- Competition in the immunotherapy space is fierce, with established players like Merck and Bristol Myers Squibb.
- Social media sentiment can be a fickle mistress, shifting rapidly based on fleeting news cycles.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PDSB Latest News
-
12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga · Aug 11, 2026
PDSB Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PDSB.
Price Targets
Wall Street price target analysis for PDSB.
PDSB MoonshotScore
What does this score mean?
The MoonshotScore rates PDSB 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Frank K. Bedu-Addo
CEO
Frank K. Bedu-Addo serves as the CEO of PDS Biotechnology Corporation. His background includes extensive experience in the pharmaceutical and biotechnology industries, with a focus on drug development and commercialization. He has held leadership positions in various companies, contributing to strategic planning, clinical development, and business development initiatives. His expertise spans across multiple therapeutic areas, including oncology and infectious diseases. He is responsible for managing 24 employees.
Track Record: Under Frank K. Bedu-Addo's leadership, PDS Biotechnology has advanced its lead product candidate, PDS0101, into Phase II clinical trials. He has also overseen the expansion of the company's preclinical pipeline and the establishment of strategic collaborations with organizations like the National Institutes of Health and Merck. His tenure has been marked by a focus on innovation and the development of novel cancer immunotherapies.
PDS Biotechnology Corporation Healthcare Stock: Key Questions Answered
What does the AI Score mean for PDSB?
PDSB holds an AI Score of 24/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company specializing in the development of cancer immunotherapies. Their lead product candidate, PDS0101 (HPV16), is currently …
What does PDS Biotechnology Corporation do?
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies and vaccines. The company's core technology is the VERSATILE platform, which aims to enhance the body's immune response to fight cancer cells. Their lead product candidate, PDS0101, is in Phase II clinical trials, targeting recurrent/metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. They are also developing vaccine candidates for infectious diseases.
What do analysts say about PDSB stock?
Analyst coverage of PDSB is limited, reflecting its status as a clinical-stage biopharmaceutical company. Generally, analysts focus on the potential of the VERSATILE platform and the progress of PDS0101 in Phase II clinical trials. Valuation metrics are heavily influenced by the projected success of the clinical pipeline and the potential for future revenue streams.
What are the main risks for PDSB?
PDSB faces several key risks inherent to the biotechnology industry. These include the risk of unfavorable clinical trial results, which could halt the development of its product candidates. Regulatory hurdles and delays in obtaining marketing approvals pose another significant risk. The company also faces competition from larger pharmaceutical companies and other biotech firms developing similar therapies.
What are the key factors to evaluate for PDSB?
PDS Biotechnology Corporation (PDSB) holds an AI score of 24/100 (low). PDS Biotechnology Corporation presents a notable research candidate due to its innovative VERSATILE platform and promising clinical pipeline. Not financial advice.
How frequently does PDSB data refresh on this page?
PDSB's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PDSB's recent stock price performance?
PDS Biotechnology Corporation (PDSB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative VERSATILE platform for cancer immunotherapy. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PDSB overvalued or undervalued right now?
PDS Biotechnology Corporation (PDSB) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PDSB before investing?
Before investing in PDS Biotechnology Corporation (PDSB), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Clinical trial outcomes are inherently uncertain and can impact the company's prospects.